| Dr Timothy Wells King, MD, PHD | |
|
2160 S 1st Ave, Maywood, IL 60153-3328 | |
| (708) 216-9000 | |
| Not Available |
| Full Name | Dr Timothy Wells King |
|---|---|
| Gender | Male |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 23 Years |
| Location | 2160 S 1st Ave, Maywood, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861514986 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | 34866 (Alabama) | Secondary |
| 208200000X | Plastic Surgery | 52045 (Wisconsin) | Secondary |
| 208200000X | Plastic Surgery | 036117954 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Loyola University Medical Center | Maywood, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Loyola University Medical Center | 3779488903 | 863 |
News Archive
The research team at Lyon has developed an animal model carrying a mutation of the DCC gene. Mice carrying the mutation develop tumours, because this gene can no longer induce the death of the cancer cells. This discovery could lead to the development of a new targeted cancer treatment that aims to reactivate the dying of cancer cells.
ACM Global Central Laboratory, a diagnostic central laboratory specializing in delivering high quality testing services which optimize clinical trial outcomes, today announced it has acquired Phoenix Pharma Central Services Pte. Ltd, a premier central laboratory services provider for Asia Pacific clinical trials, with laboratory facilities in Singapore and Shanghai, China. The acquisition enables ACM Global to deliver increased operational and financial efficiencies to clients conducting clinical studies in the Asia Pacific region. Terms of the transaction were not disclosed.
Raptor Pharmaceutical Corp., today announced that the first patient has been dosed in its Phase 2 clinical trial of DR Cysteamine for the potential treatment of Huntington's Disease. The Phase 2 clinical trial is being conducted under a previously announced collaboration agreement with The Centre Hospitalier Universitaire d'Angers ("CHU d'Angers"), which has commenced enrolling patients at eight clinical sites throughout France.
Studying two rare inherited cancer syndromes, Yale Cancer Center scientists have found the cancers are driven by a breakdown in how cells repair their DNA.
› Verified 4 days ago
| Entity Name | Loyola University Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336159961 PECOS PAC ID: 3779488903 Enrollment ID: O20031202000027 |
News Archive
The research team at Lyon has developed an animal model carrying a mutation of the DCC gene. Mice carrying the mutation develop tumours, because this gene can no longer induce the death of the cancer cells. This discovery could lead to the development of a new targeted cancer treatment that aims to reactivate the dying of cancer cells.
ACM Global Central Laboratory, a diagnostic central laboratory specializing in delivering high quality testing services which optimize clinical trial outcomes, today announced it has acquired Phoenix Pharma Central Services Pte. Ltd, a premier central laboratory services provider for Asia Pacific clinical trials, with laboratory facilities in Singapore and Shanghai, China. The acquisition enables ACM Global to deliver increased operational and financial efficiencies to clients conducting clinical studies in the Asia Pacific region. Terms of the transaction were not disclosed.
Raptor Pharmaceutical Corp., today announced that the first patient has been dosed in its Phase 2 clinical trial of DR Cysteamine for the potential treatment of Huntington's Disease. The Phase 2 clinical trial is being conducted under a previously announced collaboration agreement with The Centre Hospitalier Universitaire d'Angers ("CHU d'Angers"), which has commenced enrolling patients at eight clinical sites throughout France.
Studying two rare inherited cancer syndromes, Yale Cancer Center scientists have found the cancers are driven by a breakdown in how cells repair their DNA.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Timothy Wells King, MD, PHD 2160 S 1st Ave, Maywood, IL 60153-3328 Ph: (708) 216-9000 | Dr Timothy Wells King, MD, PHD 2160 S 1st Ave, Maywood, IL 60153-3328 Ph: (708) 216-9000 |
News Archive
The research team at Lyon has developed an animal model carrying a mutation of the DCC gene. Mice carrying the mutation develop tumours, because this gene can no longer induce the death of the cancer cells. This discovery could lead to the development of a new targeted cancer treatment that aims to reactivate the dying of cancer cells.
ACM Global Central Laboratory, a diagnostic central laboratory specializing in delivering high quality testing services which optimize clinical trial outcomes, today announced it has acquired Phoenix Pharma Central Services Pte. Ltd, a premier central laboratory services provider for Asia Pacific clinical trials, with laboratory facilities in Singapore and Shanghai, China. The acquisition enables ACM Global to deliver increased operational and financial efficiencies to clients conducting clinical studies in the Asia Pacific region. Terms of the transaction were not disclosed.
Raptor Pharmaceutical Corp., today announced that the first patient has been dosed in its Phase 2 clinical trial of DR Cysteamine for the potential treatment of Huntington's Disease. The Phase 2 clinical trial is being conducted under a previously announced collaboration agreement with The Centre Hospitalier Universitaire d'Angers ("CHU d'Angers"), which has commenced enrolling patients at eight clinical sites throughout France.
Studying two rare inherited cancer syndromes, Yale Cancer Center scientists have found the cancers are driven by a breakdown in how cells repair their DNA.
› Verified 4 days ago
Dr. Lohith Bose, MD Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 2160 S 1st Ave, Ems Bldg 110, Room 3210, Maywood, IL 60153 Phone: 708-327-3041 Fax: 708-327-3489 | |
Adam T Gould, Plastic Surgery Medicare: Medicare Enrolled Practice Location: 2160 S 1st Ave, Maywood, IL 60153 Phone: 708-327-3041 | |
Joel Bronstein, M.D. Plastic Surgery Medicare: Medicare Enrolled Practice Location: 2160 S 1st Ave, Maywood, IL 60153 Phone: 708-216-9000 |